The bone-protective effect of the phytoestrogen genistein is mediated via ERα-dependent mechanisms and strongly enhanced by physical activity

Bone

Volumn 40, Issue 6, 2007, Pages 1529-1535

  Hertrampf, T ^a   Gruca, M J ^a   Seibel, J ^a   Laudenbach, U ^a   Fritzemeier, K H ^b   Diel, P ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Estrogen receptor alpha; Estrogen receptor beta; Estrogens; Genistein; Phytoestrogens

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENISTEIN; PHYTOESTROGEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE DENSITY; BONE MINERAL; CHEMICAL STRUCTURE; CONTROLLED STUDY; FEMALE; NONHUMAN; PHYSICAL ACTIVITY; RAT; STATISTICAL SIGNIFICANCE; TRABECULAR BONE;

ANIMALS; BONE DENSITY; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN RECEPTOR ALPHA; FEMALE; GENISTEIN; MOTOR ACTIVITY; OVARIECTOMY; PHYTOESTROGENS; PHYTOTHERAPY; RATS; RATS, WISTAR;

EID: 34249072897     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.02.006     Document Type: Article

References (46)

1. Turner R.T., Riggs B.L., and Spelsberg T.C. Skeletal effects of estrogen. Endocr. Rev. 15 3 (1994) 275-300 (Review)
2. Riggs B.L., Khosla S., and Melton L.J. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23 3 (2002) 279-302 (Review)
3. Baker L., Meldrum K.K., Wang M., Sankula R., Vanam R., Raiesdana A., et al. The role of estrogen in cardiovascular disease. J. Surg. Res. 115 2 (2003) 325-344 (Review)
4. Nichols K.C., Schenkel L., and Benson H. 17 beta-Estradiol for postmenopausal estrogen replacement therapy. Obstet. Gynecol. Surv. 39 4 (1984) 230-245
5. Greendale G.A., Lee N.P., and Arriola E.R. The menopause. Lancet 353 9152 (1999) 571-580 (Review)
6. Michaelsson K., Baron J.A., Johnell O., Persson I., and Ljunghall S. Variation in the efficacy of hormone replacement therapy in the prevention of hip fracture. Swedish Hip Fracture Study Group. Osteoporos. Int. 8 6 (1998) 540-546
7. Beral V., and Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 9382 (2003) 419-427
8. Jolly E.E., Bjarnason N.H., Neven P., Plouffe Jr. L., Johnston Jr. C.C., Watts S.D., et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 10 4 (2003) 337-344
9. Lo S.S., and Vogel V.G. Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs). Best Pract. Res. Clin. Endocrinol. Metab. 18 1 (2004) 97-111 (Review)
10. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., and Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U. S. A. 93 12 (1996) 5925-5930
11. Gustafsson J.A. An update on estrogen receptors. Semin. Perinatol. 24 1 (2000) 66-69 (Review)
12. Gustafsson J.A. What pharmacologists can learn from recent advances in estrogen signalling. Trends Pharmacol. Sci. 24 9 (2003) 479-485 (Review)
13. Koehler K.F., Helguero L.A., Haldosen L.A., Warner M., and Gustafsson J.A. Reflections on the discovery and significance of estrogen receptor beta. Endocr. Rev. 26 3 (2005) 465-478 (Review)
14. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., and van der Saag P.T. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139 10 (1998) 4252-4263
15. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138 3 (1997) 863-870
16. Plouffe Jr. L. Selective estrogen receptor modulators (SERMs) in clinical practice. J. Soc. Gynecol. Investig. 7 1 Suppl. (2000) S38-S46 (Review)
17. Gluck O., and Maricic M. Skeletal and nonskeletal effects of raloxifene. Curr. Osteoporos. Rep. 1 3 (2003) 123-128
18. Albertazzi P., and Sharma S. Urogenital effects of selective estrogen receptor modulators: a systematic review. Climacteric 8 3 (2005) 214-220
19. Diel P. Tissue-specific estrogenic response and molecular mechanisms. Toxicol. Lett. 127 1-3 (2002) 217-224 (Review)
20. Ohmichi M., Tasaka K., Kurachi H., and Murata Y. Molecular mechanism of action of selective estrogen receptor modulator in target tissues. Endocr. J. 52 2 (2005) 161-167 (Review)
21. Fitzpatrick L.A. Phytoestrogens-mechanism of action and effect on bone markers and bone mineral density. Endocrinol. Metab. Clin. N. Am. 32 1 (2003) 233-252 (Review)
22. Barkhem T., Carlsson B., Nilsson Y., Enmark E., Gustafsson J., and Nilsson S. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol. Pharmacol. 54 1 (1998) 105-112
23. Pike A.C., Brzozowski A.M., Hubbard R.E., Bonn T., Thorsell A.G., Engstrom O., et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 18 17 (1999) 4608-4618
24. Hillisch A., Peters O., Kosemund D., Muller G., Walter A., Schneider B., et al. Dissecting physiological roles of estrogen receptor alpha and beta with potent selective ligands from structure-based design. Endocrinol. 18 7 (2004) 1599-1609
25. Hegele-Hartung C., Siebel P., Peters O., Kosemund D., Muller G., Hillisch A., et al. Impact of isotype-selective estrogen receptor agonists on ovarian function. Proc. Natl. Acad. Sci. U. S. A. 101 14 (2004) 5129-5134
26. 2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats. Cardiovasc. Res. 67 4 (2005) 604-612
27. Diel P., Geis R.B., Caldarelli A., Schmidt S., Leschowsky U.L., Voss A., et al. The differential ability of the phytoestrogen genistein and of estradiol to induce uterine weight and proliferation in the rat is associated with a substance specific modulation of uterine gene expression. Mol. Cell. Endocrinol. 30 221(1-2) (2004) 21-32
28. Hertrampf T., Schmidt S., Laudenbach-Leschowsky U., Seibel J., and Diel P. Tissue-specific modulation of cyclooxygenase-2 (Cox-2) expression in the uterus and the v. cava by estrogens and phytoestrogens. Mol. Cell. Endocrinol. 243 1-2 (2005) 51-57
29. Ohlsson C., Hellberg N., Parini P., Vidal O., Bohlooly M., Rudling M., et al. Obesity and disturbed lipoprotein profile in estrogen receptor-alpha-deficient male mice. Biochem. Biophys. Res. Commun. 278 3 (2000) 640-645
30. Heine P.A., Taylor J.A., Iwamoto G.A., Lubahn D.B., and Cooke P.S. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc. Natl. Acad. Sci. U. S. A. 97 23 (2000) 12729-12734
31. Mueller S.O., and Korach K.S. Estrogen receptors and endocrine diseases: lessons from estrogen receptor knockout mice. Curr. Opin. Pharmacol. 1 6 (2001) 613-619 (Review)
32. Yeung J., and Yu T.F. Effects of isoflavones (soy phyto-estrogens) on serum lipids: a meta-analysis of randomized controlled trials. Nutr. J. 19 2 (2003) 15
33. Ogawa S., Chan J., Gustafsson J.A., Korach K.S., and Pfaff D.W. Estrogen increases locomotor activity in mice through estrogen receptor alpha: specificity for the type of activity. Endocrinology 144 1 (2003) 230-239
34. Garey J., Morgan M.A., Frohlich J., McEwen B.S., and Pfaff D.W. Effects of the phytoestrogen coumestrol on locomotor and fear-related behaviors in female mice. Horm. Behav. 40 1 (2001) 65-76
35. Patisaul H.B., Melby M., Whitten P.L., and Young L.J. Genistein affects ER beta- but not ER alpha-dependent gene expression in the hypothalamus. Endocrinology 143 6 (2002) 2189-2197
36. Walf A.A., and Frye C.A. Betaeta-selective estrogen receptor modulators produce antianxiety behavior when administered systemically to ovariectomized rats. Neuropsychopharmacology 30 9 (2005) 1598-1609
37. Balasch J. Sex steroids and bone: current perspectives. Hum. Reprod. Updat. 9 3 (2003) 207-222 (Review)
38. Lee Y.B., Lee H.J., Kim K.S., Lee J.Y., Nam S.Y., Cheon S.H., et al. Evaluation of the preventive effect of isoflavone extract on bone loss in ovariectomized rats. Biosci. Biotechnol. Biochem. 68 5 (2004) 1040-1045
39. Lindberg M.K., Alatalo S.L., Halleen J.M., Mohan S., Gustafsson J.A., and Ohlsson C. Estrogen receptor specificity in the regulation of the skeleton in female mice. J. Endocrinol. 171 2 (2001) 229-236
40. Lindberg M.K., Moverare S., Skrtic S., Alatalo S., Halleen J., Mohan S., et al. Two different pathways for the maintenance of trabecular bone in adult male mice. J. Bone Miner. Res. 17 4 (2002) 555-562
41. Arjmandi B.H. The role of phytoestrogens in the prevention and treatment of osteoporosis in ovarian hormone deficiency. J. Am. Coll. Nutr. 20 5 Suppl. (2001) 398S-402S
42. Setchell K.D., and Lydeking-Olsen E. Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. Am. J. Clin. Nutr. 78 3 Suppl. (2003) 593S-609S (Review)
43. Fanti P., Monier-Faugere M.C., Geng Z., Schmidt J., Morris P.E., Cohen D., et al. The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats. Osteoporos. Int. 8 3 (1998) 274-281
44. Zhou S., Turgeman G., Harris S.E., Leitman D.C., Komm B.S., Bodine P.V., et al. Estrogens activate bone morphogenetic protein-2 gene transcription in mouse mesenchymal stem cells. Mol. Endocrinol. 17 1 (2003 (Jan)) 56-66
45. Jia T.L., Wang H.Z., Xie L.P., Wang X.Y., and Zhang R.Q. Daidzein enhances osteoblast growth that may be mediated by increased bone morphogenetic protein (BMP) production. Biochem. Pharmacol. 65 5 (2003) 709-715
46. Hertrampf T., Degen G.H., Kaid A.A., Laudenbach-Leschowsky U., Seibel J., and Di Virgilio A.L. Combined effects of physical activity, dietary isoflavones and 17beta-estradiol on movement drive, body weight and bone mineral density in ovariectomized female rats. Planta Med. 72 6 (2006 (May)) 484-487